<?xml version="1.0" encoding="UTF-8"?><abstracts-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:dn="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:ait="http://www.elsevier.com/xml/ani/ait" xmlns:ce="http://www.elsevier.com/xml/ani/common" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/abstract/scopus_id/85113445828</prism:url><dc:identifier>SCOPUS_ID:85113445828</dc:identifier><eid>2-s2.0-85113445828</eid><pubmed-id>34433919</pubmed-id><prism:doi>10.1038/s41573-021-00283-5</prism:doi><dc:title>mRNA vaccines for infectious diseases: principles, delivery and clinical translation</dc:title><prism:aggregationType>Journal</prism:aggregationType><srctype>j</srctype><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><citedby-count>10</citedby-count><prism:publicationName>Nature Reviews Drug Discovery</prism:publicationName><dc:publisher>Nature Research</dc:publisher><source-id>20425</source-id><prism:issn>14741784 14741776</prism:issn><prism:volume>20</prism:volume><prism:issueIdentifier>11</prism:issueIdentifier><prism:startingPage>817</prism:startingPage><prism:endingPage>838</prism:endingPage><prism:pageRange>817-838</prism:pageRange><prism:coverDate>2021-11-01</prism:coverDate><openaccess>1</openaccess><openaccessFlag>true</openaccessFlag><dc:creator><author seq="1" auid="57218191561"><ce:initials>N.</ce:initials><ce:indexed-name>Chaudhary N.</ce:indexed-name><ce:surname>Chaudhary</ce:surname><ce:given-name>Namit</ce:given-name><preferred-name><ce:initials>N.</ce:initials><ce:indexed-name>Chaudhary N.</ce:indexed-name><ce:surname>Chaudhary</ce:surname><ce:given-name>Namit</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/57218191561</author-url><affiliation id="60027950" href="https://api.elsevier.com/content/affiliation/affiliation_id/60027950"/></author></dc:creator><dc:description><abstract xmlns="" original="y" xml:lang="eng"><publishercopyright>Â© 2021, Springer Nature Limited.</publishercopyright><ce:para>Over the past several decades, messenger RNA (mRNA) vaccines have progressed from a scepticism-inducing idea to clinical reality. In 2020, the COVID-19 pandemic catalysed the most rapid vaccine development in history, with mRNA vaccines at the forefront of those efforts. Although it is now clear that mRNA vaccines can rapidly and safely protect patients from infectious disease, additional research is required to optimize mRNA design, intracellular delivery and applications beyond SARS-CoV-2 prophylaxis. In this Review, we describe the technologies that underlie mRNA vaccines, with an emphasis on lipid nanoparticles and other non-viral delivery vehicles. We also overview the pipeline of mRNA vaccines against various infectious disease pathogens and discuss key questions for the future application of this breakthrough vaccine platform.</ce:para></abstract></dc:description><link href="https://api.elsevier.com/content/abstract/scopus_id/85113445828" rel="self"/><link href="https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&amp;scp=85113445828&amp;origin=inward" rel="scopus"/><link href="https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&amp;scp=85113445828&amp;origin=inward" rel="scopus-citedby"/></coredata><affiliation id="60027950" href="https://api.elsevier.com/content/affiliation/affiliation_id/60027950"><affilname>Carnegie Mellon University</affilname><affiliation-city>Pittsburgh</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation id="60023009" href="https://api.elsevier.com/content/affiliation/affiliation_id/60023009"><affilname>Penn Medicine</affilname><affiliation-city>Philadelphia</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><authors><author seq="1" auid="57218191561"><ce:initials>N.</ce:initials><ce:indexed-name>Chaudhary N.</ce:indexed-name><ce:surname>Chaudhary</ce:surname><ce:given-name>Namit</ce:given-name><preferred-name><ce:initials>N.</ce:initials><ce:indexed-name>Chaudhary N.</ce:indexed-name><ce:surname>Chaudhary</ce:surname><ce:given-name>Namit</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/57218191561</author-url><affiliation id="60027950" href="https://api.elsevier.com/content/affiliation/affiliation_id/60027950"/></author><author seq="2" auid="7102689458"><ce:initials>D.</ce:initials><ce:indexed-name>Weissman D.</ce:indexed-name><ce:surname>Weissman</ce:surname><ce:given-name>Drew</ce:given-name><preferred-name><ce:initials>D.</ce:initials><ce:indexed-name>Weissman D.</ce:indexed-name><ce:surname>Weissman</ce:surname><ce:given-name>Drew</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/7102689458</author-url><affiliation id="60023009" href="https://api.elsevier.com/content/affiliation/affiliation_id/60023009"/></author><author seq="3" auid="35609935600"><ce:initials>K.A.</ce:initials><ce:indexed-name>Whitehead K.A.</ce:indexed-name><ce:surname>Whitehead</ce:surname><ce:given-name>Kathryn A.</ce:given-name><preferred-name><ce:initials>K.A.</ce:initials><ce:indexed-name>Whitehead K.A.</ce:indexed-name><ce:surname>Whitehead</ce:surname><ce:given-name>Kathryn A.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/35609935600</author-url><affiliation id="60027950" href="https://api.elsevier.com/content/affiliation/affiliation_id/60027950"/><affiliation id="60027950" href="https://api.elsevier.com/content/affiliation/affiliation_id/60027950"/></author></authors></abstracts-retrieval-response>